Compare Mondaycom Ltd (MNDY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Merck & Co., Inc. — how do they compare? Mondaycom Ltd trades at $81.4 (market cap $3.43B), while Merck & Co., Inc. trades at $148 (market cap $363.98B). The key difference: Merck & Co., Inc. is far larger — about 106.1× Mondaycom Ltd's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| MNDY | MRK | |
|---|---|---|
Market Cap | $3.43B | $363.98B |
Sector | Technology | Health |
52-Week High | $219.15 | $156.43 |
52-Week Low | $58.81 | $77.60 |
Enterprise Value | $2.59B | $410.75B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNDY trades at $83.67, down 8.13% over 24 hours, with a bearish technical signal but strong fundamentals including 88.74% gross margins and consecutive earnings beats. Revenue grew to $1.23B in 2025, though net cash flow turned negative in 2026. Recent news highlights inclusion in growth stock lists and AI-driven monetization gains.
Outlook is mixed: analyst consensus is bullish with a $106 price target, but technical weakness and negative cash flow trends pose risks. The stock offers growth potential from operational efficiency and market positioning, yet investors face volatility from competitive pressures and execution challenges.
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
